Table II.
Demographics and clinical characteristics of patients with injection site reactions
| No. | Biologic | Sex | Age (y) | Location | Injection no. at onset of 1st ISR (inj) | Onset after inj | Duration | Symptom/s | Recurrence | BMI (kg/m2) | Comorbidity |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Ixekizumab | F | 73 | Thigh | 1st | 1 d | 2-3 d | Erythema, pain, edema | Yes | – | |
| 2 | Ixekizumab | F | 52 | Arm | 1st | Several hrs | 1 d | Erythema, pain | Yes | 22.7 | Hyperlipidemia |
| 3 | Ixekizumab | F | 54 | Abdomen | 14th | 2-3 d | Continuous | Erythema, pain, eczema | Yes | 38 | Schizophrenia |
| 4 | Ixekizumab | F | 60 | Abdomen | 1st | Immediately | 1 h | Pain | Yes | – | Panic disorder |
| 5 | Ixekizumab | M | 31 | Arm | 1st | 1 h | 2-3 d | Erythema, pruritus, edema | Yes | 20.7 | Hepatitis |
| 6 | Ixekizumab | F | 55 | Abdomen | 1st | Immediately | 3-4 d | Erythema, pruritus, pain, edema | Yes | 26.1 | Asthma |
| 7 | Ixekizumab | M | 30 | Arm | 1st | 1 h | 1-2 d | Erythema, pain, edema | Yes | – | |
| 8 | Ixekizumab | F | 40 | Arm | 25th | Several hrs | 7 d | Erythema | No | 16.6 | Chronic kidney disease, urinary stone |
| 9 | Ixekizumab | M | 31 | Arm | 1st | Immediately | 2-3 d | Edema | Yes | – | |
| 10 | Ixekizumab | M | 51 | Arm | 16th | Immediately | 1 day | Pain, edema | Yes | 23 | |
| 11 | Ixekizumab | F | 49 | Abdomen | 1st | Immediately | 10 d | Erythema, pruritus, pain | Yes | 18.5 | Fibromyalgia |
| Risankizumab | Arm | 1st | 1 d | 2-3 d | Erythema, pruritus | Yes | |||||
| 12 | Guselkumab | M | 49 | Arm | 5th | 1 d | 1-2 d | Erythema, pruritus | Yes | 22.4 | Diabetes mellitus |
| 13 | Guselkumab | F | 54 | Arm | 5th | Several hrs | 2-3 d | Erythema | Yes | 24.1 | Hypothyroidism |
| 14 | Guselkumab | M | 40 | Abdomen | 7th | Several hrs | 2-3 d | Erythema, pruritus, edema | Yes | 22.5 | |
| 15 | Guselkumab | F | 28 | Arm | 3rd | 1 h | 3 h | Pruritus, wheal | Yes | 23.1 | Epilepsy |
| 16 | Guselkumab | F | 64 | Arm | 1st | Several hrs | Continuous | Pain | Yes | – | |
| 17 | Guselkumab | F | 32 | Arm | 4th | Immediately | 1-3 d | Erythema, pain, edema | Yes | – | |
| 18 | Adalimumab | M | 54 | Abdomen | 1st | 1 h | 1 d | Erythema, pruritus | Yes | 21.4 |
BMI, Body mass index; ISR, injection site reactions.